OmniSeq News

Cancer-testis antigen detection by targeted RNA sequencing

Abstract Background: Cancer-testis antigens (CTAs) have restricted expression in normal adult tissues but have been found to be overexpressed in multiple tumors.  This and their ability to elicit spontaneous cellular and humoral immune responses have rendered CTAs as...

Cancer testis antigen co-expression landscape in solid tumors

Abstract Background Cancer testis antigens (CTAs) are tumor antigens that have a highly tissue-restricted expression but are often expressed in diverse malignancies. With their highly immunogenic expression limited to tumor cells, CTAs have become a prime target for...

OmniSeq Receives ISO Certification for Quality Management Systems

BUFFALO, N.Y., Dec. 1, 2020 /PRNewswire/ -- OmniSeq®, an innovator in next generation sequencing (NGS) in oncology, today announced the company has received the International Organization for Standards (ISO) 13485:2016 certification for its Quality Management Systems...

Follow Us on Twitter

LabCorp (LH) Boosts Precision Oncology With INSIGHT NGS Launch | NASDAQ

Labcorp’s powering the next breakthrough with OmniSeq INSIGHT—launching today! Our new oncology test for all solid tumors. Learn more:

Breaking news! @Labcorp and @OmniSeq launch OmniSeq Insight, a next-generation sequencing platform to advance precision #oncology by providing evidence-based, personalized treatment recommendations based on the genomic profiling of a patient’s solid tumor.

We have a long way to go with integrative bio marker testing. Some like @OmniSeq are pioneering integrated genomic and immune profiling assays to have a more comprehensive understanding of the tumor immune micro-environment.


We have to do better! @IASLC

Load More...